Rigel Pharmaceuticals (NASDAQ: RIGL)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Rigel Pharmaceuticals Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Rigel Pharmaceuticals Company Info
The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.
News & Analysis
More data is needed.
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
The company announced positive results from an important COVID-19 clinical study.
Here's why this stock's big run-up in recent months could be just the beginning.
The company is teaming up with Eli Lilly on the development of a promising immune disease drug.
The biotechnology company is hoping to improve coronavirus care.
Success in clinical trials doesn't guarantee success on the market.
Following the announced buyout of Dermira, Eli Lilly’s management said more acquisitions are in store for 2020.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 03/22/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
RIGL earnings call for the period ending September 30, 2020.
RIGL earnings call for the period ending June 30, 2020.
RIGL earnings call for the period ending March 31, 2020.
RIGL earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.